Contact
searchSearch
HMP Global
Login

Colorectal Cancer

Colorectal Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Gunnar Folprecht, MD, PhD
Videos
Clinical Utility of ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer
07/01/2026
Gunnar Folprecht, MD, PhD
Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...
Gunnar Folprecht, MD, PhD, discusses results from the CIRCULATE trial showing that tumor-informed circulating tumor DNA testing identified patients with stage II colon cancer who derived significant benefit from adjuvant chemotherapy,...
Gunnar Folprecht, MD, PhD,...
07/01/2026
Oncology
Paul Oberstein, MD
Videos
Amivantamab Demonstrates Activity in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
05/27/2026
Paul Oberstein, MD
Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.
Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.
Paul Oberstein, MD, discusses...
05/27/2026
Oncology
Ismail Gögenur, MD, DMSc
Videos
Neoadjuvant Pembrolizumab in Localized Mismatch Repair–Deficient Colon Cancer
05/15/2026
Ismail Gögenur, MD
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc,...
05/15/2026
Oncology
Andrew Renehan, MD, PhD
Videos
Survival and Quality of Life Drive Treatment Preferences in Rectal Cancer
04/16/2026
Andrew Renehan, MD, PhD
Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.
Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.
Andrew Renehan, MD, PhD,...
04/16/2026
Oncology
Davide Ciardiello, MD
Videos
HER2 Alterations Predict Inferior Survival With Anti-EGFR Therapy in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
03/11/2026
Davide Ciardiello, MD
Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...
Davide Ciardiello, MD, discusses exploratory findings from the CAPRI-2 GOIM trial assessing the clinical impact of HER2 alterations in patients with RAS/BRAFV600 wild-type, microsatellite-stable metastatic colorectal cancer receiving...
Davide Ciardiello, MD, discusses...
03/11/2026
Oncology
Veronica Conca, MD
Videos
mFOLFOXIRI Plus Panitumumab Improves Overall Survival in RAS/BRAF Wild-Type mCRC
03/10/2026
Veronica Conca, MD
Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.
Veronica Conca, MD, discusses final results from the phase 3 TRIPLETE study comparing first-line mFOLFOXIRI plus panitumumab versus mFOLFOX plus panitumumab in RAS/BRAF wild-type metastatic colorectal cancer.
Veronica Conca, MD, discusses...
03/10/2026
Oncology
Campbell Roxburgh, MD
Videos
Short-Course Radiotherapy Shows Immunologic Advantages in Locally Advanced Rectal Cancer
02/10/2026
Campbell Roxburgh, MD
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses findings from a serial sampling study evaluating immune effects of neoadjuvant radiotherapy regimens in patients with locally advanced rectal cancer.
Campbell Roxburgh, MD, discusses...
02/10/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
ctDNA-Guided Selection Optimizes Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
Anti-EGFR Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib Plus Cetuximab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
01/16/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses results from Cohort 3 of the phase 3 BREAKWATER study evaluating encorafenib plus cetuximab with FOLFIRI versus control therapy in previously untreated BRAF V600E-mutant metastatic colorectal cancer.
Scott Kopetz, MD, PhD, discusses...
01/16/2026
Oncology

Recent News

News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma
07/10/2026
Emily Estrada
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved...
07/10/2026
Oncology
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
News
Brain Radiotherapy Plus Continued Systemic Therapy Improves Survival in Brain-Only Progressive Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter cohort study demonstrated that continuing the original systemic therapy plus brain radiotherapy improved survival in patients with extensive-stage small cell lung cancer who developed brain-only progression after...
Results from a multicenter...
07/09/2026
Oncology
News
Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma
07/09/2026
Stephanie Holland
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...
Results from a phase 1 trial...
07/09/2026
Oncology
News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
News
Aglatimagene Plus Radiotherapy Improves Disease-Free Survival in Localized Prostate Cancer
07/09/2026
Emily Estrada
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy significantly improved disease-free survival in patients with intermediate- to high-risk...
Results from the phase 3 PrTK03...
07/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use